Beth Taylor Biography and Net Worth

CFO of Inotiv

Beth Taylor joined Inotiv in March 2020, with an extensive background in corporate and operational finance and accounting. She possesses exceptional experience and expertise in business planning, technical accounting, compliance, and investor relations for public companies, and a successful track record of cultivating support and relationships within organizations to achieve goals.

Prior to joining Inotiv, Beth held progressively responsible VP of Finance, Controllership and other financial leadership positions at Endocyte, Inc., Author Solutions, Inc., Harlan Laboratories, Inc., Republic Airways Holdings and Rolls-Royce Corporation. She started her career in audit with Deloitte and received her B.S. in Accounting from Indiana University’s Kelly School of Business in Bloomington, Indiana.

What is Beth A. Taylor's net worth?: The estimated net worth of Beth A. Taylor is at least $1.61 thousand as of February 17th, 2026. Ms. Taylor owns 145,480 shares of Inotiv stock worth more than $1,615 as of October 13th. This net worth evaluation does not reflect any other investments that Ms. Taylor may own. Learn More about Beth A. Taylor's net worth.
How do I contact Beth A. Taylor?: The corporate mailing address for Ms. Taylor and other Inotiv executives is 2701 KENT AVENUE, WEST LAFAYETTE IN, 47906. Inotiv can also be reached via phone at (765) 463-4527 and via email at [email protected]. Learn More on Beth A. Taylor's contact information.
Has Beth A. Taylor been buying or selling shares of Inotiv?: Beth A. Taylor has not been actively trading shares of Inotiv during the last quarter. Most recently, Beth A. Taylor sold 2,888 shares of the business's stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $0.29, for a transaction totalling $837.52. Following the completion of the sale, the chief financial officer now directly owns 145,480 shares of the company's stock, valued at $42,189.20. Learn More on Beth A. Taylor's trading history.
Who are Inotiv's active insiders?: Inotiv's insider roster includes Philip Downing (VP), John Sagartz (Insider), and Beth Taylor (CFO). Learn More on Inotiv's active insiders.
Are insiders buying or selling shares of Inotiv?: During the last year, insiders at the sold shares 5 times. They sold a total of 25,817 shares worth more than $10,755.03. The most recent insider tranaction occured on February, 17th when CFO Beth A. Taylor sold 2,888 shares worth more than $837.52. Insiders at Inotiv own 7.8% of the company. Learn More about insider trades at Inotiv.
Information on this page was last updated on 2/17/2026.

Beth A. Taylor Insider Trading History at Inotiv

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
2/17/2026	Sell	2,888	$0.29	$837.52	145,480

Beth A. Taylor Buying and Selling Activity at Inotiv

Inotiv Company Overview

Inotiv, Inc. provides nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries. It operates through two segment: Discovery and Safety Assessment (DSA), and Research Models and Services (RMS). The DMS segment manufactured scientific instruments for life sciences research and the related software for use by pharmaceutical companies, universities, government research centers, and medical research institutions under the Company's BASi product line. The RMS segment engages in commercial production and sales of research models, diets, bedding, and bioproducts. The company offers research and discovery services, including computational toxicology, disease pharmacology, DMPK, safety pharmacology, discovery bioanalysis, exploratory, surgical models and medical device, and cell and molecular biology; non-clinical safety assessment includes general and genetic toxicology, regulated bioanalysis, carcinogenicity studies, and development and reproductive toxicology; pathology services, such as histology, digital, clinical, and medical device pathology; bioanalysis includes nonregulated discovery bioanalysis, biotherapeutics, and regulated preclinical and clinical bioanalysis; proteomics; and consulting services, as well as model and research services. The company operates in the United States, the Netherlands, and internationally. The company was formerly known as Bioanalytical Systems, Inc. and changed its name to Inotiv, Inc. in March 2021. Inotiv, Inc. was incorporated in 1974 and is headquartered in West Lafayette, Indiana.

Today's Range

Now: $0.01

$0.01

$0.02

50 Day Range

MA: $0.02

$0.01

$0.10

2 Week Range

Now: $0.01

$0.08

$2.95

Volume

243,786 shs

Average Volume

7,417,403 shs

Market Capitalization

$387.26 thousand

P/E Ratio

N/A

Dividend Yield

N/A

Beta

3.77